1. Home
  2. MPLT vs VALN Comparison

MPLT vs VALN Comparison

Compare MPLT & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$17.33

Market Cap

772.7M

Sector

Health Care

ML Signal

N/A

Logo Valneva SE

VALN

Valneva SE

HOLD

Current Price

$9.07

Market Cap

855.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPLT
VALN
Founded
2018
2012
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
772.7M
855.8M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
MPLT
VALN
Price
$17.33
$9.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$31.00
$15.75
AVG Volume (30 Days)
191.7K
13.1K
Earning Date
02-28-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$211,089,992.00
Revenue This Year
N/A
$3.64
Revenue Next Year
N/A
$12.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
13.48
52 Week Low
$12.24
$5.17
52 Week High
$21.55
$12.25

Technical Indicators

Market Signals
Indicator
MPLT
VALN
Relative Strength Index (RSI) 46.41 44.46
Support Level $17.06 $9.20
Resistance Level $19.34 $10.09
Average True Range (ATR) 1.54 0.29
MACD -0.05 -0.12
Stochastic Oscillator 31.57 13.90

Price Performance

Historical Comparison
MPLT
VALN

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: